Welcome to our dedicated page for Iterum Therapeutics Plc SEC filings (Ticker: ITRM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Searching Iterum Therapeutics’ latest disclosures but buried under technical jargon? Clinical-stage biotech reports are packed with trial statistics, FDA discussions, and cash-runway math that can stretch well past 250 pages. For investors tracking antibiotic innovators, missing a single footnote could mean overlooking a pivotal clinical milestone or dilution warning.
Stock Titan solves that problem. Our AI reads every Iterum Therapeutics quarterly earnings report 10-Q filing, Iterum Therapeutics annual report 10-K simplified, and Iterum Therapeutics 8-K material events explained in real time, then delivers plain-English summaries of R&D spend, Fast Track designations, and trial results. Need to monitor Iterum Therapeutics insider trading Form 4 transactions? Receive alerts on Iterum Therapeutics Form 4 insider transactions real-time so you instantly see when executives buy or sell shares.
Every document type is covered:
- 10-K & 10-Q: cash runway, pipeline updates, risk factors—Iterum Therapeutics SEC filings explained simply
- 8-K: outcome of Phase 3 studies, FDA feedback
- DEF 14A: Iterum Therapeutics proxy statement executive compensation tied to clinical milestones
- Form 4: Iterum Therapeutics executive stock transactions Form 4 for insider sentiment
With our AI-powered summaries, you’ll quickly access Iterum Therapeutics earnings report filing analysis, compare quarter-over-quarter R&D trends, and assess how new data might impact valuation—all without combing through endless pages. Stay informed with comprehensive coverage, real-time updates, and expert context that turns dense biotech filings into actionable insights.
Equity Residential (EQR) – Form 4 insider filing
Director Tahsinul Zia Huque received 3,393 Series 2025D restricted units (RUs) of ERP Operating Limited Partnership on 1 July 2025 as part of the REIT’s annual long-term compensation program. Each RU automatically converts, subject to tax-capital targets, into one OP Unit that is exchangeable for one Equity Residential common share (or cash) at the company’s option.
- Vesting: 1 July 2026
- Post-vesting holding restriction: until 1 July 2027
- Expiration: 1 July 2035 (if conversion target not met)
- Ownership form: Direct
No shares were sold; the grant was recorded at $0 cost, indicating a routine equity-based award rather than an open-market purchase. The transaction modestly increases insider equity alignment but is immaterial to EQR’s capital structure.
FAQ
What is the current stock price of Iterum Therapeutics Plc (ITRM)?
What is the market cap of Iterum Therapeutics Plc (ITRM)?
What is the primary focus of Iterum Therapeutics Plc?
Which therapeutic area does Iterum primarily target?
How does Iterum generate value within its business model?
What regulatory designations has the company received?
How does Iterum address the challenge of antibiotic resistance?
What distinguishes Iterum’s product portfolio in the pharmaceutical market?
